Clinical trial
BLOOD BRAIN BARRIER DYSFUNCTION IN GLIOMA AND EPILEPTOGENESIS
NCT07909460 is registered in ClinicalTrials.gov with University College, London as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- BLOOD BRAIN BARRIER DYSFUNCTION IN GLIOMA AND EPILEPTOGENESIS
- Lead sponsor
- University College, London
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- January 4, 2027
- Completion date
- January 4, 2030
- Enrollment
- 56 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 3 arms.
-
Glioma with epilepsy
participants with glioma and tumour-related epilepsy.
-
Glioma without epilepsy
participants with glioma who do not have epilepsy.
-
control group
participants without glioma or epilepsy
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Differences in inflammatory markers in people with glioma and healthy controls, as well as between people with glioma with and without epilepsy.
inflammatory markers will be defined as blood brain barrier leakage using filter exchange imaging
Lead sponsor's other trials
University College, London, most recent start first.
+645 more trials See the organization page
Similar trials
Same condition (Epilepsy) and phase, most recent start first.
+534 more trials See the condition page